# Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

> **NCT04974671** · PHASE2 · RECRUITING · sponsor: **Yale University** · enrollment: 30 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Oligoprogressive
- Progression

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT04974671
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-22
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04974671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04974671, "Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04974671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*